(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer. Metsera has declared Novo's offer superior, and given Pfizer until Tuesday to raise its bid. The U.S. Federal Trade Commission granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews. The waiting period was originally set to e ...

法律行动 - 辉瑞公司于周五对Metsera和诺和诺德提起诉讼 [1] - 诉讼指控上述两家公司违反合并协议并干扰交易 [1]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera. Pfizer alleges that the Novo Nordisk offer cannot qualify as a "Superior Company Proposal†u. ...

股市表现 - 美国三大股指均收涨，道琼斯工业平均指数上涨69.54点（0.15%）至47,591.66点，标准普尔500指数上涨21.48点（0.31%）至6,843.82点，纳斯达克综合指数表现最强，上涨165.60点（0.70%）至23,746.74点 [2] 制药行业公司动态 - 辉瑞公司（PFE）以49亿美元收购Metsera的交易获得美国联邦贸易委员会（FTC）的早期许可，此举旨在加强其在竞争激烈的肥胖和心血管代谢疾病市场的产品管线 [3] - 强生公司（JNJ）向美国食品药品监督管理局（FDA）提交了Stelara®（ustekinumab）的补充生物制剂许可申请，寻求批准该药物用于治疗两岁及以上中重度活动性溃疡性结肠炎儿科患者，以扩大其市场 [4] 经济与加密货币趋势 - 国际货币基金组织（IMF）预测2025年美国经济增长率为2.0% [5] - 高盛报告指出加密货币目前占全球总投资组合的1% [5] - 联邦检察官指控比特币ATM被用于促进加密货币诈骗 [6] 能源政策 - 据报道，白宫已从其未来石油租赁计划中移除大西洋区域，这标志着联邦能源政策的转变 [7]

While many investors focus on semiconductors and AI or the growth sector, one of my Economic Modern Family members has been busy.The Biotech Sector ETF (NASDAQ: IBB), has made new multi-year highs. We cannot say new all-time highs as that was made in 2021 during Covid.However, we can discount that unusual time and safely say the Biotech Sector ETF (IBB) is on a tear and could very well continue. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty ...

Key Takeaways Pfizer will report Q3 2025 earnings before market open, with sales estimated at $16.6 billion.Earnings estimates have fallen to $3.06 per share amid rising costs from recent acquisitions.Higher sales of Vyndaqel, Padcev and Eliquis may have supported growth despite IRA headwinds.Pfizer (PFE) will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $16.6 billion and 66 cents per share, respe ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. (NASDAQ:MTSR) jumped to a new 52-week high of $66.10 before trimming gains to end the day just up by 22.06 percent at $63.73 apiece. This fo ...

财报发布日程 - 周五盘前能源巨头埃克森美孚公司和雪佛龙公司领衔发布财报 同时还有艾伯维公司 [1] - 下周一盘后Palantir Technologies Inc发布财报 [1] - 下周二主要财报包括Shopify Inc、优步技术公司、辉瑞公司和超微半导体公司 [1] - 下周三盘后科技行业成为焦点 包括Applovin公司、高通公司和Arm Holdings plc [1] - 下周四盘前阿斯利康PLC和康菲石油公司发布财报 [1] - 下周五发布关键财报的包括金融公司KKR & Co Inc和公用事业公司Constellation Energy Corporation [1]

Pfizer logo on glass office building facade with sky reflections, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)Gado via Getty ImagesNovo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer.The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the highly lucrative weight-loss drug market. Novo Nordisk, already dominant wi ...

Italy's largest bank by assets reported a slight drop in net profit to €2.37 billion as lower interest rates ate into its top line. ...